Results 11 to 20 of about 4,529 (167)
The Beta-1-Receptor Blocker Nebivolol Elicits Dilation of Cerebral Arteries by Reducing Smooth Muscle [Ca2+]i. [PDF]
PLoS ONE, 2016 Nebivolol is known to have beta-1 blocker activity, but it was also suggested that it elicits relaxation of the peripheral arteries in part via release of nitric oxide (NO).
Peter Cseplo +5 more
doaj +1 more source
MODERN POTENTIAL IN THE TREATMENT OF METABOLIC SYNDROME PATIENTS - FOCUS ON ENDOTHELIUM
Российский кардиологический журнал, 2014 Numerous publications on the use of p-blockers in patients with arterial hypertension (AH) and metabolic syndrome (MS) have reported adverse effects of these medications on carbohydrate and lipid metabolism, as well as reduced cerebral perfusion.
V. B. Mychka +5 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2016 Aim. To evaluate influence of long-term monotherapy with nebivolol on blood pressure (BP) (office BP; self-monitoring BP, pre-trip BP monitoring, ambulatory BP monitoring (ABPM)) and metabolic blood profile in locomotive crew staff with newly diagnosed ...
I. V. Osipova +6 more
doaj +1 more source
Analytical approaches for the determination of Nebivolol [PDF]
Records of Pharmaceutical & Biomedical Sciences, 2022 A highly selective ẞ1-adrenergic receptor antagonist, nebivolol has a unique pharmacologic profile from other medications in its class. Nebivolol causes nitric oxide-mediated vasodilation in addition to cardioselectivity mediated by ẞ1 receptor blockage ...
Fathalla Belal +4 more
doaj +1 more source
Frontiers in Medicine, 2022 BackgroundTenofovir disoproxil fumarate (TDF), a widely prescribed component in antiretroviral regimens, has been associated with nephrotoxicity. Nebivolol is a third generation selective β-1 adrenergic receptor blocker and may protect renal structure ...
Mariana Moura Nascimento +6 more
doaj +1 more source
Journal of Pharmacy & Pharmaceutical Sciences, 2017 Purpose: To investigate whether fluvoxamine coadministration can influence the pharmacokinetic properties of nebivolol and its active hydroxylated metabolite (4-OH-nebivolol) and to assess the consequences of this potential pharmacokinetic interaction ...
Ana-Maria Gheldiu +10 more
doaj +1 more source
American Journal Cardiovascular Drugs, 2009 Nebivolol is a beta-adrenergic receptor antagonist with a dual mechanism of action. It shows high selectivity for beta(1)-adrenergic receptors and appears to have nitric oxide-mediated vasodilatory activity. Once-daily nebivolol effectively lowered BP in patients with mild to moderate hypertension in four randomized, double-blind, placebo-controlled ...
Claudine M, Baldwin, Susan J, Keam
openaire +3 more sources
Archives of Medical Science, 2019 Introduction Overactive bladder (OAB) is a disease that significantly decreases quality of life. Adverse effects of the drugs currently used in OAB treatment limit their use in patients with hypertension. Nebivolol (a β 1 -adrenergic receptor blocker) is
Andrzej F. Wróbel +4 more
doaj +1 more source
Effects of Metoprolol and Nebivolol on Exercise Blood Pressure in Patients with Mild Hypertension
The Scientific World Journal, 2013 Objectives. We planned to compare the impact of two beta blockers, metoprolol and nebivolol, on arterial blood pressure during exercise in patients with mild hypertension. Methods.
Huseyin Ugur Yazici +3 more
doaj +1 more source